Synapse - Department of Medicine

Results (39711)

A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination with trametinib, in mutant BRAF V600 solid tumors

Meeting Abstract

McKean, M.; Spira, A. I.; Rosen, E.; Subbiah, V.; Moreno, V.; Gambardella, V.; Vieito, M.; Saavedra, O.; Cousin, S.; Cassier, P. A.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors

Meeting Abstract

Janjigian, Y. Y.; Oaknin, A.; Lang, J. M.; Ciombor, K. K.; Ray-Coquard, I. L.; Oza, A. M.; Yonemori, K.; Xu, R. H.; Zhao, J.; Gajavelli, S.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

First-in-human clinical trial design of a first-in-class theranostic approach with a peptide-based radioligand targeting CA IX-expressing tumors

Meeting Abstract

Feldman, D. R.; Tran, B.; Emmett, L.; Hofman, M. S.; Olivier, P.; Mahammedi, H.; Galetic, I.; Pokorska-Bocci, A.; Bouisset, F.; Gollmer, K.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

FRONTIER: FAPi radioligand open-label, phase 1 study to evaluate safety, tolerability and dosimetry of [Lu-177]-PNT6555—A dose escalation study for treatment of patients with select solid tumors

Meeting Abstract

Bodei, L.; Kavan, P.; Liberman, M.; Taunk, N.; Metser, U.; Juneau, D.; O'Reilly, E. M.; Ma, J.; Cioci, R.; Abdul Razak, A. R.
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

A single-arm phase 2 study of peri-operative immune checkpoint inhibition and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer

Meeting Abstract

McArthur, H. L.; Comen, E. A.; Bryce, Y.; Solomon, S. B.; Leal, J. H. S.; Abaya, C. D.; Martinez, C.; Basho, R. K.; McAndrew, P.; Larkin, B.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC)

Meeting Abstract

Mayer, E. L.; Tolaney, S. M.; Brufsky, A.; Gradishar, W. J.; Jhaveri, K. L.; Martin, M.; Moscetti, L.; Schneeweiss, A.; Vidal, G. A.; Cortazar, P.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Harnessing olaparib, palbociclib, and endocrine therapy: A phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA mutation-associated, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (HOPE)

Meeting Abstract

Torres, A.; Aaron, M.; White, L.; D'Andrea, K.; Narayan, V.; Knollman, H. M.; Bradbury, A. R.; Tung, N. M.; Robson, M. E.; Nathanson, K.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

The ARETHA study: A phase 2 randomized control trial of eribulin with evexomostat (SDX-7320) or placebo for patients with metastatic triple-negative breast cancer (TNBC) and metabolic dysfunction

Meeting Abstract

Shen, S.; Solomon, V.; Williams, D.; Robson, M. E.; Norton, L.; Traina, T. A.; Iyengar, N. M.
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Early integration of exercise into breast cancer care: The MSK healthy living program

Meeting Abstract

Rowed, K.; Shen, S.; Smith, A.; Kelly, B.; Magnoli, R.; Corcoran, S.; Emerzian, M.; Ackerman, K.; Cruz, C.; Salehi, E.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Dermocosmetics in management of cancer-related skin toxicities: International expert consensus

Meeting Abstract

Dreno, B.; Khosrotehrani, K.; De Barros Silva, G.; Ryan-Wolf, J.; Kerob, D.; Trombetta, M. G.; Atenguena Okobalemba, E.; Dielenseger, P.; Pan, M.; Lacouture, M. E.
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save